Protective Mechanisms of Butyrate on Inflammatory Bowel Disease

Author(s): João P.B. Silva, Kely C. Navegantes-Lima, Ana L.B. Oliveira, Dávila V.S. Rodrigues, Sílvia L.F. Gaspar, Valter V.S. Monteiro, Davi P. Moura, Marta C. Monteiro*.

Journal Name: Current Pharmaceutical Design

Volume 24 , Issue 35 , 2018

Become EABM
Become Reviewer

Abstract:

Inflammatory bowel disease (IBD) is a multifactorial chronic disease, commonly associated with alteration in the composition and function of gut microbiota. This process can lead to a decreased production of short chain fatty acids (SCFAs) by the gut microbiota, mainly butyrate, which is an important immunomodulatory molecule in the intestine. Butyrogenic bacteria normally produces butyrate through carbohydrate fermentation or amino acids degradation pathways. This molecule plays an important protective role in intestinal homeostasis acting in both adaptive immunity and innate immunity. This review summarizes the current knowledge about the role of butyrate on the development of IBD and the protective mechanisms of this metabolite on the intestinal mucosa and the whole body, as reported by in vitro and in vivo studies. Thus, butyrate can regulate the activation of regulatory T cells, increasing the acetylation of histones and decreasing the activation of NF-κB. In addition, it can also stimulate the mucus production from epithelial cells and the rearrangement of tight junction proteins.

Keywords: Butyrate, Short chain fatty acids, inflammatory bowel disease, IBD, inflammation, ulcerative Colitis, Crohn's disease.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 24
ISSUE: 35
Year: 2018
Page: [4154 - 4166]
Pages: 13
DOI: 10.2174/1381612824666181001153605
Price: $58

Article Metrics

PDF: 32
HTML: 1